Replies to post #785849 on NorthWest Biotherapeutics Inc (NWBO)

[barnstormer]

Self-explanatory - Any form of financing that doesn't require the company to give up shares.

[RobotDroid]

That would be when the pos ceo and nonmanagement actually bought shares on the open market instead of grifting them with rigged voting, an event THAT WILL NEVER EVER HAPPEN BECAUSE THEY KNOW THIS FAILED.

[LessIsMore]

What is "non dilutive financing"

There are many methods of non-dilutive financing.

Many times a royalty (usually % of sales) is negotiated for a multi-tiered financing agreement which includes an upfront payment. This can be done before approval.

Recent example (yesterday):

8:35 AM EDT, 09/02/2025 (MT Newswires) -- Zenas BioPharma (ZBIO) and Royalty Pharma (RPRX) said Tuesday that the latter will offer up to $300 million in financing in exchange for a royalty on sales of monoclonal antibody obexelimab.

Obexelimab is in phase 3 development to treat immunoglobulin G4-related disease (IgG4-RD), and phase 2 development for relapsing multiple sclerosis and systemic lupus erythematosus (SLE), the companies said.

Under the deal, Royalty Pharma will receive a 5.5% royalty on global net sales of obexelimab by Zenas in exchange for an upfront payment of $75 million and three additional payments of $75 million based on the achievement of certain benchmarks.

Zenas said the financing will support a potential commercial roll out of obexelimab for IgG4-RD in H1 2027, subject to the US Food and Drug Administration approval.